Asia-Pacific Clinical Nutrition Market - Segmented by Route of Administration, Disease Type, End-user, and Geography - Growth, Trends, and Forecast (2018 - 2023)
The Asia-Pacific clinical nutrition market is expected to register a CAGR of 7.9%, during the forecast period, 2018 to 2023. Clinical nutrition is an area of medicine that offers treatment of medical disorders caused due to an improper diet or due to the body’s inability to absorb the nutrients available in a normal diet. Clinical nutrition products include clinical foods and dietary supplements that are categorized primarily as pharmaceuticals and are delivered through enteral and parenteral feeding. They are aimed at treating metabolic disorders, eating or nutritional disorders, and others.
Increasing Prevalence of Metabolic Disorders
The prevalence of metabolic disorders has increased over the past decade; however, this is only in terms of raw data. The actual number of patients going for the diagnosis of metabolic disorders has increased over the decade, hence, an increase in the number of patients diagnosed. Most of the metabolic syndromes result in situations where body lacks the capability to synthesize non-essential molecules, like vitamins, amino acids, and several molecules involved in metabolic pathways. Most of these conditions can be managed only with supplementation of one or two nutrients. For instance, vitamin D deficiency can be managed simply by using vitamin D tablets. But, the market is large, owing to metabolic disorders that last for a lifetime. Hence, once diagnosed, a patient becomes a lifelong customer, thus, compensating the low cost of single units. This, combined with increase in the number of patients being diagnosed with metabolic syndromes, is driving the growth of the clinical nutrition market. The other factor, such as high spending on healthcare is driving the Asia-Pacific clinical nutrition market.
Unwillingness of Hospitals and In-house Pharmacies/Dispencaries to Maintain the Required Stock of Clinical Nutrition Products
Unlike developed nations, like United States or European countries, where the regulators can mandate maintaining stocks of some products in in-house pharmacies/dispensaries, along with retail pharmacies, no such regulation exists in emerging markets and third-world countries. This leaves maintaining the stock of any product at the sole discretion of people running the pharmacies/dispensaries (both in-house and retail). As a result, the owners of pharmacies and dispensaries mostly prefer to maintain the stocks of products that have quick turnaround. This results in the products, such as clinical nutrition or anti-venoms, being rarely kept in stock in the pharmacies/dispensaries, owing to high turnaround time for clinical nutrition products and the doctors in emerging and third world countries mostly suggesting clinical nutrition alternatives to their patients, keeping in mind their financial conditions. Hence, most pharmacies and dispensaries (in-house and retail) in emerging and third world countries do not maintain stocks of clinical nutrition products as two-third of the world population belong to the third world countries. This is restraining the growth of the Asia-Pacific clinical nutrition market. The other factor, such as heterogenous nature of government coverage/reimbursement across countries and imprecise perception about clinical nutrition is also hindering the growth of the market.
China Lead the Market in Asia-Pacific Region
The China clinical nutrition market holds the largest market share in 2017 in Asia-Pacific region due to the presence of high quality healthcare system and the majority of Asian countries are still developing with countries, like India, which in-spite of having good GDP per capita, are facing huge income disparities. This condition is leading to poor affordability of proper nutrition to most people. This chronic malnutrition is the major contributor to the growth of the clinical nutrition market in these regions.
Key Developments in the Market: